<DOC>
	<DOC>NCT00593827</DOC>
	<brief_summary>The purpose of this study was to determine the effects of the weekly regimen of ixabepilone dosing compared to the once every 3 week dosing regimen in participants with metastatic breast cancer.</brief_summary>
	<brief_title>Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Has MBC that is measurable by RECIST or has nonmeasurable disease with serum CA27.29 (or CA15.3) ≥ 50 Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer Prior chemotherapy is permitted with no limit on the number of prior regimens Two weeks or more have elapsed since last chemotherapy or radiation treatment Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 02 Is female, ≥ 18 yrs of age Protocol defined appropriate laboratory values Negative pregnancy test within 7 calendar days prior to registration Has signed a patient informed consent Had prior treatment with ixabepilone or other epothilones Has HER2+ disease Has a known, prior, severe (National Cancer Institute Common Terminology Criteria Adverse Events [NCI CTCAE] Grade 34) history of hypersensitivity reaction to a drug formulated in Cremophor ® EL (polyoxyethylated castor oil) Is receiving concurrent immunotherapy, hormonal therapy or radiation therapy Is receiving concurrent investigational therapy or has received such therapy within the past 30 days Has peripheral neuropathy &gt; Grade 1 Has evidence of central nervous system (CNS) involvement requiring radiation or steroid treatment. Participants with stable brain metastases who are off steroids at least 2 weeks are eligible Is pregnant or breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>